Adiponectin levels in myeloma patients after curcumin supplementation: A randomized clinical pilot study

Background: Multiple myeloma (MM) is characterized by reduced circulating adiponectin levels, a condition associated with various diseases such as diabetes mellitus, obesity, cardiovascular diseases, cancer, and plasma dyscrasias. Curcumin has been shown to inhibit adipogenesis and elevate serum adi...

Full description

Saved in:
Bibliographic Details
Main Authors: Damai Santosa, Damar Mashkun Rizqi, Eko Adhi Pangarsa, Budi Setiawan, Suyono Suyono, Mika Lumban Tobing, Suhartono Suhartono, Soeharyo Hadisaputro, Ignatius Riwanto, Aru Wisaksono Sudoyo, Catharina Suharti
Format: Article
Language:English
Published: Babol University of Medical Sciences 2025-03-01
Series:Caspian Journal of Internal Medicine
Subjects:
Online Access:http://caspjim.com/article-1-4177-en.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849701773027049472
author Damai Santosa
Damar Mashkun Rizqi
Eko Adhi Pangarsa
Budi Setiawan
Suyono Suyono
Mika Lumban Tobing
Suhartono Suhartono
Soeharyo Hadisaputro
Ignatius Riwanto
Aru Wisaksono Sudoyo
Catharina Suharti
author_facet Damai Santosa
Damar Mashkun Rizqi
Eko Adhi Pangarsa
Budi Setiawan
Suyono Suyono
Mika Lumban Tobing
Suhartono Suhartono
Soeharyo Hadisaputro
Ignatius Riwanto
Aru Wisaksono Sudoyo
Catharina Suharti
author_sort Damai Santosa
collection DOAJ
description Background: Multiple myeloma (MM) is characterized by reduced circulating adiponectin levels, a condition associated with various diseases such as diabetes mellitus, obesity, cardiovascular diseases, cancer, and plasma dyscrasias. Curcumin has been shown to inhibit adipogenesis and elevate serum adiponectin levels. Notably, limited studies investigating the relationship between adiponectin levels and curcumin supplementation in myeloma patients. This study is to evaluate the efficacy curcumin supplements on increasing the levels of adiponectin in myeloma patients Methods: Patients with myeloma were randomly to melphalan, prednisone, curcumin (MPC) (n=17) and melphalan with prednisone (MP) (n=16) groups. The MPC group was treated by melphalan 4 mg/m2 and prednisone 40 mg/m2 for 7 days (MP), and curcumin 8 grams daily for 28 days. The MP group received MP and placebo. Subjects were followed-up every 28 days and a total of four treatment cycles. Hemoglobin, albumin, white blood cell (WBC), platelets, urea, creatinine, calcium, protein M, and adiponectin evaluated before and after treatment. Mann Whitney test or the Independent T-test were used to analysis Results: Total subject (24 subjects) completed the treatment. Serum adiponectin levels after four treatment cycles in the MPC group were higher than in the MP group [(mean, 12227.1±5748.3) vs (11365.4±9175.5), P = 0.78] Conclusion: Supplementing MP regimen with 8000 mg curcumin daily for 28 days increases the serum adiponectin level after four treatment cycles in myeloma patients. This research found that myeloma patients may benefit by taking curcumin supplementation.
format Article
id doaj-art-ec268d881ffe4b61899aaa9d32dfc330
institution DOAJ
issn 2008-6164
2008-6172
language English
publishDate 2025-03-01
publisher Babol University of Medical Sciences
record_format Article
series Caspian Journal of Internal Medicine
spelling doaj-art-ec268d881ffe4b61899aaa9d32dfc3302025-08-20T03:17:51ZengBabol University of Medical SciencesCaspian Journal of Internal Medicine2008-61642008-61722025-03-01162320327Adiponectin levels in myeloma patients after curcumin supplementation: A randomized clinical pilot studyDamai Santosa0Damar Mashkun Rizqi1Eko Adhi Pangarsa2Budi Setiawan3Suyono Suyono4Mika Lumban Tobing5Suhartono Suhartono6Soeharyo Hadisaputro7Ignatius Riwanto8Aru Wisaksono Sudoyo9Catharina Suharti10 Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital, Jawa Tengah, Indonesia Department of Internal Medicine, RSUD Hj. Anna Lasmanah Banjarnegara, Jawa Tengah, Indonesia Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital, Jawa Tengah, Indonesia Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital, Jawa Tengah, Indonesia Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital, Jawa Tengah, Indonesia Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital, Jawa Tengah, Indonesia Department of Environmental Health, Faculty of Public Health, Diponegoro University, Jawa Tengah, Indonesia Division of Topical and Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital, Jawa Tengah, Indonesia Department of Surgery, Faculty of Medicine, Diponegoro University, Semarang, Indonesia Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital – Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia. Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital, Jawa Tengah, Indonesia Background: Multiple myeloma (MM) is characterized by reduced circulating adiponectin levels, a condition associated with various diseases such as diabetes mellitus, obesity, cardiovascular diseases, cancer, and plasma dyscrasias. Curcumin has been shown to inhibit adipogenesis and elevate serum adiponectin levels. Notably, limited studies investigating the relationship between adiponectin levels and curcumin supplementation in myeloma patients. This study is to evaluate the efficacy curcumin supplements on increasing the levels of adiponectin in myeloma patients Methods: Patients with myeloma were randomly to melphalan, prednisone, curcumin (MPC) (n=17) and melphalan with prednisone (MP) (n=16) groups. The MPC group was treated by melphalan 4 mg/m2 and prednisone 40 mg/m2 for 7 days (MP), and curcumin 8 grams daily for 28 days. The MP group received MP and placebo. Subjects were followed-up every 28 days and a total of four treatment cycles. Hemoglobin, albumin, white blood cell (WBC), platelets, urea, creatinine, calcium, protein M, and adiponectin evaluated before and after treatment. Mann Whitney test or the Independent T-test were used to analysis Results: Total subject (24 subjects) completed the treatment. Serum adiponectin levels after four treatment cycles in the MPC group were higher than in the MP group [(mean, 12227.1±5748.3) vs (11365.4±9175.5), P = 0.78] Conclusion: Supplementing MP regimen with 8000 mg curcumin daily for 28 days increases the serum adiponectin level after four treatment cycles in myeloma patients. This research found that myeloma patients may benefit by taking curcumin supplementation.http://caspjim.com/article-1-4177-en.pdfmultiple myelomacurcuminadiponectin
spellingShingle Damai Santosa
Damar Mashkun Rizqi
Eko Adhi Pangarsa
Budi Setiawan
Suyono Suyono
Mika Lumban Tobing
Suhartono Suhartono
Soeharyo Hadisaputro
Ignatius Riwanto
Aru Wisaksono Sudoyo
Catharina Suharti
Adiponectin levels in myeloma patients after curcumin supplementation: A randomized clinical pilot study
Caspian Journal of Internal Medicine
multiple myeloma
curcumin
adiponectin
title Adiponectin levels in myeloma patients after curcumin supplementation: A randomized clinical pilot study
title_full Adiponectin levels in myeloma patients after curcumin supplementation: A randomized clinical pilot study
title_fullStr Adiponectin levels in myeloma patients after curcumin supplementation: A randomized clinical pilot study
title_full_unstemmed Adiponectin levels in myeloma patients after curcumin supplementation: A randomized clinical pilot study
title_short Adiponectin levels in myeloma patients after curcumin supplementation: A randomized clinical pilot study
title_sort adiponectin levels in myeloma patients after curcumin supplementation a randomized clinical pilot study
topic multiple myeloma
curcumin
adiponectin
url http://caspjim.com/article-1-4177-en.pdf
work_keys_str_mv AT damaisantosa adiponectinlevelsinmyelomapatientsaftercurcuminsupplementationarandomizedclinicalpilotstudy
AT damarmashkunrizqi adiponectinlevelsinmyelomapatientsaftercurcuminsupplementationarandomizedclinicalpilotstudy
AT ekoadhipangarsa adiponectinlevelsinmyelomapatientsaftercurcuminsupplementationarandomizedclinicalpilotstudy
AT budisetiawan adiponectinlevelsinmyelomapatientsaftercurcuminsupplementationarandomizedclinicalpilotstudy
AT suyonosuyono adiponectinlevelsinmyelomapatientsaftercurcuminsupplementationarandomizedclinicalpilotstudy
AT mikalumbantobing adiponectinlevelsinmyelomapatientsaftercurcuminsupplementationarandomizedclinicalpilotstudy
AT suhartonosuhartono adiponectinlevelsinmyelomapatientsaftercurcuminsupplementationarandomizedclinicalpilotstudy
AT soeharyohadisaputro adiponectinlevelsinmyelomapatientsaftercurcuminsupplementationarandomizedclinicalpilotstudy
AT ignatiusriwanto adiponectinlevelsinmyelomapatientsaftercurcuminsupplementationarandomizedclinicalpilotstudy
AT aruwisaksonosudoyo adiponectinlevelsinmyelomapatientsaftercurcuminsupplementationarandomizedclinicalpilotstudy
AT catharinasuharti adiponectinlevelsinmyelomapatientsaftercurcuminsupplementationarandomizedclinicalpilotstudy